Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 4Neoplasms 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2Sepsis 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Pathologic Complete Response 1Neutropenia 1Neuroblastoma 1Neoplasm Metastasis 1Multiple Myeloma 1Malignant mesenchymal tumor 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Diseases 1Graft vs Host Disease 1Gliosarcoma 1Glioblastoma 1Fever 1Carcinoma, Renal Cell 1Brain Neoplasms 1

Interventions

Sunitinib 20Nivolumab 16cabozantinib 12Sorafenib 12pembrolizumab 11pazopanib 9Ipilimumab 9Interferon-alpha 9belzutifan 8Everolimus 8lenvatinib 7Bevacizumab 7aldesleukin 6Magnetic Resonance Spectroscopy 6Axitinib 6atezolizumab 5Interferon alpha-2 4temsirolimus 3Specimen Handling 3Radiosurgery 3Nephrectomy 3Interleukin-2 3tivozanib 2durvalumab 2avelumab 2Saline Solution 2G250 monoclonal antibody 2Fluorouracil 2Chemotherapy, Adjuvant 2CTLA-4 Antigen 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Renal Cell × Granulocyte-Macrophage Colony-Stimulating Factor × Clear all
NCT01265901 2017-10-12

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Immatics Biotechnologies GmbH

Phase 3 Completed
339 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡